Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
RBA.TO 0.66CEG -5.66AVGO -2.75EWW -0.68JCI -2.62NVDA -10.43IMO.TO -1.89DPM.TO -2.43
Novo-Nordisk (NVO)

NYSE:NVO

Novo-Nordisk (NVO)

45.61
-0.65 (1.41%)
as of Aug 28, 2026, 8:00:00 pm Market Open.
268 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 28, 2026, 12:00 am

This summary was created by AI, based on 33 opinions in the last 12 months.

Novo Nordisk (NVO) has seen a decline in its market position, particularly in the competitive landscape for GLP-1 drugs where Eli Lilly (LLY) is dominating. Many analysts express concerns about NVO losing market share and not capitalizing effectively on its weight-loss drug offerings. While NVO retains a high-quality franchise in diabetes management and a relatively low price-to-earnings (PE) ratio of 11x, its future growth potential appears clouded by increasing competition and pricing pressures. Recent insider buying offers a glimmer of optimism, but overall sentiment remains cautious, with expectations of only modest earnings growth. The stock's technical chart shows downward trends, leading many experts to recommend patience in assessing recovery potential before committing to long-term investments.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
WEAK BUY

Novo-Nordisk(NVO)

May 24, 2023

Traditionally, insulin. Now into weight loss, big home run, stock has charged ahead. Up 40%. Only one approved by the FDA, the leader. Stock won't go down as long as sales keep up. Market is massive. See his Top Picks.

Photo of Bruce MurrayBruce MurrayUnlock Rating
$161.85

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Apr 25, 2023

Has owned this for 20 years. They specialize in diabetes meds. They now have developed a weight-loss drug; shares have surged a lot in the past year given huge demand. NOVO can invest their cash flow into more R&D of drugs.

Photo of Brett Girard, CPA, CA, CFABrett Girard, CPA, CA, CFA
Owned
Unlock Rating
$169.95

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Feb 24, 2023

Top supplier of insulin. A very good company. Their diabetes drug has sold out so shares have plateaued. That said, he prefers Eli Lilly.

Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$141.60

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Novo-Nordisk(NVO)

Dec 12, 2022
The stock is up so much, but they produce the right medical products.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$129.43

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Aug 26, 2022

Does not own any stock in company, Has had impressive sales record with organic growth. Pressure on diabetes pricing in the USA. Expecting new products coming onto market to benefit the company. Large portion if US(40%) living with obesity. Expensive at current share price.

Photo of Michael Hakes - CFA, MBAMichael Hakes - CFA, MBAUnlock Rating
N/A

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Jun 17, 2022
Likes company and has owned shares for a long time. #1 company in European diabetic market. Share prices are a little over priced. Will continue holding shares for the long term.
Photo of Darren SissonsDarren Sissons
Owned
Unlock Rating
$105.58

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Novo-Nordisk(NVO)

May 12, 2022
NVO vs. LLY Focused on weight loss and diabetes. One issue is the liquidity, as it doesn't work well for his covered call strategy. Still fairly expensive. LLY had great weight reduction results recently. LLY is at a discounted valuation, a more diversified business, and exposure to Alzheimer's. He prefers LLY, but you'd be OK on both.
Photo of Paul MacDonaldPaul MacDonald
No
Unlock Rating
$104.48

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Novo-Nordisk(NVO)

Feb 04, 2022
(A Top Pick Feb 10/21, Up 46%) Believes company is leading insulin producer for diabetics. Revenues outside USA are increasing. Above average financial results from previous quarter was rewarded by market. Rising diabetes levels in society will be good for company. Company has very little debt and is looking at other products.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$99.67

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
COMMENT

Novo-Nordisk(NVO)

Jan 17, 2022
He was negative on this 5 years ago but now likes it and owns some for the long term. Insulin prices have normalized and it has a good weight loss drug. When asked to compare to Lilly he prefers NVO although Lilly is good too. The only concern is that this is a defensive growth stock and some might sell to buy cyclicals.
Photo of David FingoldDavid Fingold
Owned
Unlock Rating
$96.32

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Novo-Nordisk(NVO)

Oct 08, 2021
(A Top Pick Feb 10/21, Up 49%) Leading company for making insulin. The FDA approved their 2.5mg dose of weight-loss drug, which helped share prices. They are first to market with it. The expectations for earnings were moved higher. Getting more international sales in the long term. Stock is starting to get noticed by fund managers internationally.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$98.38

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Aug 31, 2021
A Danish drug company that makes insulin. He likes the pharma stocks, though have been underperforming. He owns many pharmas, but you can't own all of them.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$100.38

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Novo-Nordisk(NVO)

Jun 17, 2021
Largest producer of insulin in the world. Diabetes is one of the fastest-growing diseases. Will continue to do well.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$82.63

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Jun 07, 2021
A long time favourite. Recent news was FDA approval of a diabetes drug that can also be used for weight-loss. (Analysts’ price target is $76.50)
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$81.21

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Feb 10, 2021
Take a pill once a week instead of injecting. Big implications moving forward. International sales have gone beyond what US sales were. Good entry point for the next 5-10 years. May get more diversified over time. No debt outstanding. Yield is 1.45% (Analysts’ price target is $75.73)
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$71.22

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Novo-Nordisk(NVO)

Oct 20, 2020

It's focused 90% in diabetes products which offers a competitive advantage. He owned this before, but sold it because its options liquidity is low in the US (he trades options). Instead, he owns its direct competitor, Eli Lily, which boasts more product diversity. (Both companies have phase 3 Covid drugs.) Novo is a leader in diabetes and good to own unless you trade options.

Photo of Paul MacDonaldPaul MacDonald
No
Unlock Rating
$71.48

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
Showing 106 to 120 of 207 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

PFE -0.06$27.96
MDT 1.26$91.23
BBY -1.12$82.44
TTWO 2.39$235.39
MDT 1.26$91.23

Today's Top Picks

RBA.TO 0.66$119.68
CEG -5.66$276.75
AVGO -2.75$368.79
EWW -0.68$76.48
JCI -2.62$139.59

Popular Articles

Latest Sell Signals

EIF.TO -1.16$121.64
FTS.TO 0$76.06
ENB.TO 0.48$69.76
MCD 4.94$265
IBM -3.2$235.59

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Bill Baruch, Founder, Blue Line Capital

Bill Baruch, Founder, Blue Line Capital

Blue Line Capital

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like